Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,538

These are the First Real Nanobots Entering your Body

The Rise of actually real and useful Nanobots making use of the rapidly advancing miniaturization of robotics and microchips through companies such as TSMC, Intel and Samsung. These nanobots are soon going to enable things such as full dive virtual reality, healing diseases such as cancer and potentially even increasing the longevity up to 200 years. These tiny computer/robots will enter our bloodstream and cross the blood brain barrier to read and write similar to how Brain Computer Interfaces such as Neuralink currently work. The future of technology is looking really exciting.

If you enjoyed this video, please consider rating this video and subscribing to our channel for more frequent uploads. Thank you! smile
–
TIMESTAMPS:
00:00 Have we reached the Nanobot-Era?
02:51 The Applications of Nanobots.
04:26 All the types of BCI’s.
06:44 So, when will there be Nanobots?
09:13 Last Words.
–
#nanobots #ai #nanotechnology

Could AI allow for Infinite Storage? — The Future of DNA Storage Technology

Digital Storage Capabilities are about to increase 100x in the very near future with the biggest tech companies like Microsoft or Intel working on making DNA Storage a possibility and bringing it to consumers. This is being accomplished with advances in Artificial Intelligence models in combination with better understanding of Biotechnology. This is the future of storage technology and we may see petabytes of cheap storage in the form of AI very soon.
DNA digital data storage is the process of encoding and decoding binary data to and from synthesized strands of DNA Storage Technology.
–
If you enjoyed this video, please consider rating this video and subscribing to our channel for more frequent uploads. Thank you! smile
–
TIMESTAMPS:
00:00 Storage Today.
01:08 A new approach to Storage.
02:06 The difference between DNA and Storage.
04:30 When is the Future of Storage?
07:01 Microsoft’s Goal.
08:31 Last Words.
–
#dna #ai #storage

Analysis: Country by country, scientists eye beginning of an end to the COVID-19 pandemic

“We think between now and the end of 2,022 this is the point where we get control over this virus … where we can significantly reduce severe disease and death,” Maria Van Kerkhove, an epidemiologist leading the World Health Organization’s (WHO) COVID-19 response, told Reuters.

CHICAGO, Nov 3 (Reuters) — As the devastating Delta variant surge eases in many regions of the world, scientists are charting when, and where, COVID-19 will transition to an endemic disease in 2022 and beyond, according to Reuters interviews with over a dozen leading disease experts.

They expect that the first countries to emerge from the pandemic will have had some combination of high rates of vaccination and natural immunity among people who were infected with the coronavirus, such as the United States, the UK, Portugal and India. But they warn that SARS-CoV-2 remains an unpredictable virus that is mutating as it spreads through unvaccinated populations.

None would completely rule out what some called a “doomsday scenario,” in which the virus mutates to the point that it evades hard-won immunity. Yet they expressed increasing confidence that many countries will have put the worst of the pandemic behind them in the coming year.

Trust The AI? You Decide

Trust in AI. If you’re a clinician or a physician, would you trust this AI?

Clearly, sepsis treatment deserves to be focused on, which is what Epic did. But in doing so, they raised several thorny questions. Should the model be recalibrated for each discrete implementation? Are its workings transparent? Should such algorithms publish confidence along with its prediction? Are humans sufficiently in the loop to ensure that the algorithm outputs are being interpreted and implem… See more.

Earlier this year, I wrote about fatal flaws in algorithms that were developed to mitigate the COVID-19 pandemic. Researchers found two general types of flaws. The first is that model makers used small data sets that didn’t represent the universe of patients which the models were intended to represent leading to sample selection bias. The second is that modelers failed to disclose data sources, data-modeling techniques and the potential for bias in either the input data or the algorithms used to train their models leading to design related bias. As a result of these fatal flaws, such algorithms were inarguably less effective than their developers had promised.

Now comes a flurry of articles on an algorithm developed by Epic to provide an early warning tool for sepsis. According to the CDC, “sepsis is the body’s extreme response to an infection. It is a life-threatening medical emergency and happens when an infection you already have triggers a chain reaction throughout your body. Without timely treatment, sepsis can rapidly lead to tissue damage, organ failure, and death. Nearly 270,000 Americans die as a result of sepsis.”

Partnership to Expand Effective Gene Therapies for Rare Diseases

Rare diseases aren’t so rare. Collectively, up to 30 million Americans, many of them children, are born with one of the approximately 7,000 known rare diseases. Most of these millions of people also share a common genetic feature: their diseases are caused by an alteration in a single gene.

Many of these alterations could theoretically be targeted with therapies designed to correct or replace the faulty gene. But there have been significant obstacles in realizing this dream. The science of gene therapy has been making real progress, but pursuing promising approaches all the way to clinical trials and gaining approval from the U.S. Food and Drug Administration (FDA) is still very difficult. Another challenge is economic: for the rarest of these conditions (which is most of them), the market is so small that most companies have no financial incentive to pursue them.

To overcome these obstacles and provide hope for those with rare diseases, we need a new way of doing things. One way to do things differently—and more efficiently—is the recently launched Bespoke Gene Therapy Consortium (BGTC). It is a bold partnership of NIH, the FDA, 10 pharmaceutical companies, and several non-profit organizations [1]. Its aim: optimize the gene therapy development process and help fill the significant unmet medical needs of people with rare diseases.

What chip shortage? AMD books capacity years ahead to ease crunches

LISBON, Nov 2 (Reuters) — Chip designer Advanced Micro Devices (AMD.O) has been able to skirt most of the problems linked with the global chip supply shortage by forecasting demand years in advance, a top executive said on Tuesday.

Demand for electronics gadgets from people stuck in homes due to the pandemic has led to a shortage of semiconductors that are used from anything from mobile phones and cars.

But despite a squeeze in supply, AMD has been able to take market share away from rival Intel (INTC.O) in both PCs and servers with its latest line of processors.